Presentation of myocarditis in athletes is heterogeneous and establishing the diagnosis is challenging with no current uniform clinical gold-standard. The combined information from symptoms, electrocardiography, laboratory testing, echocardiography, cardiac magnetic resonance imaging (CMR), and in certain cases endomyocardial biopsy (EMB) helps to establish the diagnosis. Most patients with myocarditis recover spontaneously; however, athletes may be at higher risk of adverse cardiac events. Based on scarce evidence and mainly autopsy studies and expert's opinions, current recommendations generally advise abstinence from competitive sports ranging from 3 to 6 months. However, the dilemma poses that (un-) necessary prolonged disqualification of athletes in order to avoid adverse cardiac events, can cause considerable disruption to training schedules and tournament preparation, and leading to a decline in performance and ability to compete. Therefore, better risk stratification tools are needed. Using latest available data, this review contrasts existing recommendations and presents a new proposed diagnostic flowchart putting a greater focus on the use of CMR imaging in athletes with suspected myocarditis. This may enable cardiac caregivers to risk stratify athletes with suspected myocarditis more systematically, and furthermore allow for pooling of more unified data. To modify recommendations regarding sports behavior in athletes with myocarditis, more evidence, based on large multicenter registries including CMR and EMB, is needed. In the future, physicians might rely on combined novel risk stratification methods, by implementing both noninvasive-and invasive tissue characterization methods.